Keros Therapeutics (KROS) Assets Average (2020 - 2025)
Historic Assets Average for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to $750.0 million.
- Keros Therapeutics' Assets Average rose 4502.16% to $750.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $750.0 million, marking a year-over-year increase of 4502.16%. This contributed to the annual value of $493.0 million for FY2024, which is 4567.11% up from last year.
- Per Keros Therapeutics' latest filing, its Assets Average stood at $750.0 million for Q3 2025, which was up 4502.16% from $770.9 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Assets Average registered a high of $770.9 million during Q2 2025, and its lowest value of $230.9 million during Q2 2022.
- Moreover, its 5-year median value for Assets Average was $345.6 million (2023), whereas its average is $401.5 million.
- Per our database at Business Quant, Keros Therapeutics' Assets Average soared by 63682.06% in 2021 and then plummeted by 785.89% in 2022.
- Keros Therapeutics' Assets Average (Quarter) stood at $242.6 million in 2021, then grew by 15.28% to $279.7 million in 2022, then increased by 24.48% to $348.1 million in 2023, then soared by 71.65% to $597.6 million in 2024, then grew by 25.5% to $750.0 million in 2025.
- Its Assets Average was $750.0 million in Q3 2025, compared to $770.9 million in Q2 2025 and $700.2 million in Q1 2025.